Investors Eye Stem Cell Shares Amid Court Dispute
Earlier this week, U.S. District Judge Royce Lamberth hit the brakes an executive order aimed to remove “barriers to responsible research involving human stem cells,” by ruling that millions in government grants can’t be made. Late in 2009, the Obama administration sent stem cell stocks soaring after approving the first 13 human embryonic stem cell lines for use by federally funded researchers, noting “this is the first down payment on what is going to be a much longer list.”
According to USA Today, the Department of Justice plans to appeal the recent ruling, but some industry executives say the circumstances call for a more permanent resolution. Geron (NASDAQ: GERN – News) CEO Tom Okarma told Bloomberg, Lamberth’s ruling “is a clear mandate for the administration to finish what they started with the Obama executive order.” Whether any policy action could follow the ruling is unknown, but investors will be watching the Stem Cell Stocks Index closely as more details regarding the appeal process are made public.
Geron, which is the largest U.S.-listed stem cell pure-play, despite weighing in at less than $500 million, is trading roughly flat on a six-month basis amid a mixed performance by its peers. Top performers Cytori Therapeutics, Inc. (NASDAQ: CYTX – News) and Osiris Therapeutics (NASDAQ: OSIR – News) are ahead by more than 8% for the period, but laggards have declined by as much as -40%.
As of this writing, all 11 Stem Cell Stocks Index components are -30% or more from their 52-week highs with Opexa Therapeutics (NASDAQ: OPXA – News), Aastrom Biosciences (NASDAQ: ASTM – News), and Athersys Inc (NASDAQ: ATHX – News) more than -60% from their respective peaks.
It will be interesting to see whether any rulings in Washington, or the related media attention will draw traders into the stem cell sector. Investors can track the Stem Cell Stocks Index for performance trends and a suite of other metrics at tickerspy.com.
Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from dividends to ETFs to green energy to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!
http://finance.yahoo.com/news/Investors-Eye-Stem-Cell-indie-3442303503.html?x=0